Experimental Dengue Vaccine Ellicits Complete Protection in Human Model

NIAID Dengue

Dengue is caused by any of the four related viruses that are transmitted to people by Aedes mosquitoes. The World Health Organization estimates that up to 400 million dengue infections occur annually, resulting in 500,000 hospitalizations. In a clinical trial, NIAID’s live attenuated dengue vaccine, TV003, elicited complete protection against dengue in a human challenge model.

Dr. Stephen Whitehead, Senior Associate Scientist in the Laboratory of Infectious Diseases (LID), NIAID has a long history of vaccine development and identification of new agents of viral diseases. Dr. Whitehead leads a research team in LID that aims to develop a vaccine that protects against all four serotypes of dengue virus.

Category: 
Lab Spotlight
Region: 
Mid-Atlantic